If you have been reading about Lyophilisation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Consequently, cellular bodies that form through liquid–liquid phase separation are a subset of biomolecular condensates, as are those where the physical origins of assembly are unknown. Historically, many cellular non-membrane bound compartments identified microscopically fall under the broad umbrella of biomolecular condensates. In physics, phase separation can be classified into the following types of colloid, of which biomolecular condensates are one example:
The amine on AICAR is much less nucleophillic than its counterpart on GAR due to delocalization of electrons in AICAR through conjugation. Therefore, the N5 nucleophile of AIRCAR must be activated for the formylation reaction to occur. Histidine 268 and Lysine 267 have been found to be essential for catalysis and are conserved in all AICAR transformylase. Histidine 268 is involved in deprotonation of the N5 nucleophile of AICAR, whereas Lysine 267 is proposed to stabilize the tetrahedral intermediate.
==== Distribution of inefficient medicine and harms to health ==== One of the first acts under Melo's administration was to buy, among other medicines, azithromycin, ivermectin, and hydroxychloroquine and chloroquine – the latter of two which had been approved for the treatment of malaria – to supposedly combat COVID-19, despite multiple studies showing that all the medicines bought were ineffective towards treating the virus. The controversial decision was brought to suit by PSOL, which alleged that his administration was using public money to buy the medicine. The measure was also criticized by the council of the Faculty of Medicine at the Federal University of Rio Grande do Sul that asked for the immediate suspension of their distribution. Melo justified the purchase with the Ministry of Medicine by stating that people in the middle and upper-middle classes, and their friends, were taking the medicine. In total, the city government bought 239,000 reais worth of the medications, which they packaged into what they called the "COVID kit". Along with their ineffectiveness, it has been reported that the use of the medications combined over a long period and in high doses could lead to liver and renal damage, leading to the need for a liver transplant or possibly death. In February, the Justice ministry prohibited, in a liminary decision, the city from distributing the kit. In the decision, the judge argued that the prohibition would be necessary while robust evidence, based on clinical studies and recognized by the scientific community, did not exist.
=== Reproduction === Komagataella can undergo both asexual reproduction and sexual reproduction, by budding and ascospore. In this case, two types of cells of Komagataella exist: haploid and diploid cells. In the asexual life cycle, haploid cells undergo mitosis for reproduction. In the sexual life cycle, diploid cells undergo sporulation and meiosis. The growth rate of its colonies can vary by a large range, from near to 0 to a doubling time of one hour, which is suitable for industrial processes.
==== Adrenocortical carcinoma and tumors ==== Adrenocortical carcinoma occurs rarely; the average incidence rate is estimated to be 1–2 cases per million annually. The disease involves the formation of cancerous cells within the cortex of one or both of the adrenal glands. Although these tumors are identified in fewer than two percent of patients diagnosed with hyperandrogenism, the possibility must be considered within this population. In one study, more than half of tumor-affected patients had elevated levels of the androgens androstenedione, dehydroepiandrosterone sulfate, and testosterone. The elevation of androgens caused by adrenocortical carcinomas often causes patients to develop Cushing's syndrome, primary aldosteronism, and hyperandrogenism. The molecular basis of the disease has yet to be elucidated.
Sources: en.wikipedia.org
=== EC 1.6.5 With a quinone or similar compound as acceptor === EC 1.6.5.1: deleted EC 1.6.5.2: NAD(P)H dehydrogenase (quinone) EC 1.6.5.3: now EC 7.1.1.2 NADH:ubiquinone reductase (H+-translocating) EC 1.6.5.4: monodehydroascorbate reductase (NADH) EC 1.6.5.5: NADPH:quinone reductase EC 1.6.5.6: p-benzoquinone reductase (NADPH) EC 1.6.5.7: 2-hydroxy-1,4-benzoquinone reductase EC 1.6.5.8: Now EC 7.2.1.1, NADH:ubiquinone reductase (Na+-transporting) EC 1.6.5.9: NADH:ubiquinone reductase (non-electrogenic) EC 1.6.5.10: NADPH dehydrogenase (quinone) EC 1.6.5.11: Identical to EC 1.6.5.9, NADH:quinone reductase (non-electrogenic) EC 1.6.5.12: demethylphylloquinone reductase
== Characteristics == The average size of the orifice is 0.3 to 0.4 mm in diameter. There can be two or more foramina separated by a portion of dentin and cementum or by cementum only. If more than one foramen is present on each root, the largest one is designated as the apical foramen and the rest are considered accessory foramina.
== External links == Creatine+Kinase,+BB+Form at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human CKB genome location and CKB gene details page in the UCSC Genome Browser. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Still, the index closed at its all-time high of 24,121.74, for its first close above 24,000 points. The SENSEX closed at 25,019.51, for its first close above the 25,000 milestone on 5 June 2014 26,000, 7 July 2014- The SENSEX crossed record 26,000 level for the first time on 7 July 2014 and reached its peak of 26,123.55, before closing slightly lower at 26,100.08, in anticipation of strong reformatory budget by the new government. 27,000, 2 September 2014 - The SENSEX closed at 27,019.39, for its first close above the 27,000 level, on 2 September 2014. This is the sixth 1000-point milestone the index has crossed in 2014, tying a record set in 2007. 28,000, 5 November 2014 - The SENSEX crossed 28,000 mark, on 5 November 2014. One week later, on 12 November 2014, the index would close above the milestone for the first time. This is the seventh 1000-point milestone the index has crossed in 2014, breaking the six 1000-point record set in 2007. 29,000, 23 January 2015 - BSE Sensex today set a new high of 29,408 points and all-time closing high of 29,278.84, up 272.82 points 30,000, 4 March 2015 - The Sensex breaches 30000 mark following steps taken by the Reserve Bank of India in cutting the repo rates. 26 April 2017 - The SENSEX closed at 30,133.35, for its first close above the 30,000 level. 31,000, 26 May 2017- The SENSEX crossed record 31,000 level for the first time on 26 May 2017 and reached its peak of 31,074.07, before closing slightly lower at 31,028.21. 32,000, 13 July 2017 - The SENSEX closed at 32,037.38, for its first close above the 32,000 level, on 13 July 2017.
== Further reading == Sigel, Astrid; Freisinger, Eva; Sigel, Roland K.O., eds. (2020). Transition Metals and Sulfur: A Strong Relationship for Life. Guest Editors Martha E Sosa Torres and Peter M.H.Kroneck. Berlin/Boston: de Gruyter. pp. xlv+455. ISBN 978-3-11-058889-7.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.